Carrie S. Cox became the Chairman of Candel Therapeutics in May 2021. Ms. Cox is an established executive leader in the biopharmaceutical industry, both in operating roles and as a corporate director. She is also currently the Chairman of Organon, a women’s health spinoff of Merck & Co, and was recently the Chairman of Array Biopharma, which was acquired by Pfizer for $11.4 billion in 2019, as well as a Director on the Board of Celgene, which was acquired by Bristol Myers Squibb in a $74 billion transaction. Prior to her numerous board roles, she served as Executive Vice President and President of Schering-Plough’s Global Pharmaceutical Business.
Ms. Cox currently serves on the Boards of Directors of Cardinal Health, Selecta BioSciences, Texas Instruments, and Organon. She previously served as Chairman and Chief Executive Officer of Humacyte, Inc., which she joined in 2010. Ms. Cox also served as Chairman of Prism Pharmaceuticals, which was sold to Baxter Corporation in 2011. She spent her early career at Sandoz Pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility. She was later President of the Global Prescription Business at Pharmacia Corporation, Senior Vice President of Global Business Management at Pharmacia & Upjohn, as well as Vice President of Women’s Healthcare at Wyeth-Ayerst (all now Pfizer).
Fortune magazine named Ms. Cox to its List of the “50 Most Powerful Women in Business” six times. She is a graduate of the Massachusetts College of Pharmacy and Health Sciences.